Company profile for Kytopen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We enable transformative therapies with our patent-pending continuous Flowfect® cell engineering platforms. The non-viral Flowfect® technology is a fast, scalable, and gentle process that yields billions of high-quality engineered cells in minutes while maintaining cell health and function. By carefully synchronizing the pulse delivery with the fluid flow we have eliminated the harmful effects of traditional transfection v...
We enable transformative therapies with our patent-pending continuous Flowfect® cell engineering platforms. The non-viral Flowfect® technology is a fast, scalable, and gentle process that yields billions of high-quality engineered cells in minutes while maintaining cell health and function. By carefully synchronizing the pulse delivery with the fluid flow we have eliminated the harmful effects of traditional transfection via static electroporation

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
501 Massachusetts Avenue The Engine Accelerator Cambridge, MA
Telephone
Telephone
02139-4018
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Product Expo West

Natural Product Expo West

Not Confirmed

envelop Contact Supplier

Natural Product Expo West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/tq-therapeutics-gmbh-enters-into-technology-access-agreement-with-kytopen-302629672.html

PR NEWSWIRE
02 Dec 2025

https://www.prnewswire.com/news-releases/kytopen-and-excellos-explore-new-pathways-to-non-viral-cell-therapy-manufacturing-302612604.html

PR NEWSWIRE
12 Nov 2025

https://www.prnewswire.com/news-releases/kytopen-announces-collaboration-with-bluewhale-bio-to-revolutionize-cell-therapy-manufacturing-302550207.html

PR NEWSWIRE
09 Sep 2025

https://www.prnewswire.com/news-releases/kytopen-and-aldevron-expedite-cell-therapy-manufacturing-through-their-collaborative-crispr-mediated-cellular-engineering-workflow-302441388.html

PR NEWSWIRE
29 Apr 2025

https://www.prnewswire.com/news-releases/kytopen-enables-significant-advances-in-non-viral-cellular-engineering-of-monocyte-derived-macrophages-302282563.html

PR NEWSWIRE
22 Oct 2024
Kytopen Names Michael Chiu CEO
Kytopen Names Michael Chiu CEO

08 Aug 2023

// CONTRACT PHARMA

https://www.contractpharma.com/contents/view_breaking-news/2023-08-08/kytopen-names-michael-chiu-ceo/?widget=listSection

CONTRACT PHARMA
08 Aug 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty